Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?
Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor…
Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor…
Since 2014, investment in Non-Alcoholic SteatoHepatitis (NASH) has taken off with a fervor reminiscent of…
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a…
The FDA has cleared Genfit's IND application to treat a second liver disease with a…
Genfit reinforced its leading place in the race to find a cure for NASH when…
Genfit is extending the applications of its star candidate, Elafibranor, to a second liver disease -…
Genfit (France) has enroled their first patient in the highly anticipated phase III trial (RESOLVE-IT)…
Looking forward to 2016, I wondered which Biotechs I would watch closely. Here's my list…
Which part of our body do European biotechs prefer to target? And how diversified are…
Interview with Jean-François Mouney (Chairman and CEO of Genfit) at the 'Liver Meeting 2015' congress…
Does NASH mean anything to you? You should be vigilant about this market as it could…